Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2015 - 2026)
Sunshine Biopharma (SBFM) posted Total Non-Current Liabilities of $535614.0 for Q1 2026, down 10.25% on a QoQ basis from $596785.0 in Q4 2025, and down 25.84% year-over-year from $722199.0 in Q1 2025.
Sunshine Biopharma (SBFM) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Sunshine Biopharma's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $535614.0 for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 25.84% year-over-year to $535614.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $535614.0 (down 25.84% YoY) and the FY2025 annual result came in at $596785.0, down 19.86% from the prior year.
- Total Non-Current Liabilities was $535614.0 for Q1 2026 at Sunshine Biopharma, down from $596785.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $744724.0 in Q4 2024 and bottomed at $489027.0 in Q3 2024.
- A 5-year average of $618336.9 and a median of $617713.5 in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slumped 63.93% — and 2025, when it jumped 38.09%.
- Sunshine Biopharma's Total Non-Current Liabilities stood at $685264.0 in 2022, then declined by 14.23% to $587764.0 in 2023, then grew by 26.7% to $744724.0 in 2024, then declined by 19.86% to $596785.0 in 2025, then slipped by 10.25% to $535614.0 in 2026.
- Business Quant data shows SBFM's Total Non-Current Liabilities at $535614.0 in Q1 2026, $596785.0 in Q4 2025, and $636708.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 599.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 1.86 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 535,614.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 535,614.00 |
| Dec 31, 2025 | 596,785.00 |
| Sep 30, 2025 | 636,708.00 |
| Jun 30, 2025 | 706,530.00 |
| Mar 31, 2025 | 722,199.00 |
| Dec 31, 2024 | 744,724.00 |
| Sep 30, 2024 | 489,027.00 |
| Jun 30, 2024 | 511,635.00 |
| Mar 31, 2024 | 545,697.00 |
| Dec 31, 2023 | 587,764.00 |
| Sep 30, 2023 | 598,719.00 |
| Jun 30, 2023 | 639,882.00 |
| Mar 31, 2023 | 656,168.00 |
| Dec 31, 2022 | 685,264.00 |
| Dec 31, 2021 | 1.90 Mn |
| Mar 31, 2019 | 338,973.00 |
| Dec 31, 2018 | 289,847.00 |
| Dec 31, 2016 | 274,104.00 |
| Dec 31, 2015 | 1.27 Mn |